Drugs / CVL006
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06621615 | Nov 2024 → May 2028 expected | — | Convalife (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07615660 | May 2026 → Apr 2029 expected | neoplastic disease or syndrome | Convalife (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07157956 | Sep 2025 → Aug 2028 expected | neoplasm | Convalife (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CVL006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07157956 ↗ |
| Known as | B006 Injection | “CVL006（B006 Injection）、pemetrexed（Pemetrexed Disodium for Injection）、carboplatin（Carboplatin Injection）” NCT07157956 ↗ |
| Modality | Monoclonal antibody | “humanized IgG1 anti-VEGF monoclonal antibody” NCT07307053 ↗ |
| Route | Intravenous | “intravenous infusion” NCT06621615 ↗ |